Now firmly established within the social media world - with over 10, 000 Facebook fans, over 2, 500 followers on Twitter, and many more supporters across other sites - we need our online supporters to help with our 'Get Serious' campaign. 'Get Serious', underlining the seriousness of diabetes, is all about strength in numbers - so we're aiming to get as many of our existing online supporters as possible to sign up and show their commitment to Get Serious about diabetes, to boost those numbers. Help make diabetes a priority "If everyone who supports us on Facebook, Twitter and other social networks signs up to Get Serious we will increase support for the campaign by thousands, " said Paul McDonald, Head of Communications at Diabetes UK. "We're coming together with a single message: sign up to show your commitment to Get Serious about diabetes. By signing up, you join a community that is fighting one of the UK's biggest health challenges. Each person who signs up to Get Serious brings us one step closer to making diabetes a priority for everyone.
In patients with type 2 diabetes, silent cerebral infarction (SCI) small areas of brain damage caused by injury to small blood vessels signals an increased risk of progressive kidney disease and kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). If SCI is present in the brain, it could be an indicator that small-vessel damage is present in the kidneys as well, suggests the new study by Takashi Uzu, MD (Shiga University School of Medicine, Otsu, Japan). Uzu comments, "Silent cerebral infarction may be a new marker to identify patients who are risk for declining kidney function." The study included 608 patients with type 2 diabetes, all initially free of symptomatic stroke, heart disease, or kidney disease (overt proteinuria or renal dysfunction). On magnetic resonance imaging (MRI) scans of the brain, 177 of the patients (29 percent) had SCI subtle areas of brain damage caused by disease of the brain blood vessels, but not severe enough to cause overt symptoms of stroke.
Having diabetes can feel like a balancing act among blood glucose (sugar) levels, food, exercise and the ways in which each of these elements affects day-to-day life. Add to this more than 12 hours of dancing each day in pointe shoes, late-night performances and flip-flopping diagnoses, and it's no wonder that ballerina Zippora Karz "felt like a human yo-yo." Diabetes Forecast, the consumer magazine of the American Diabetes Association, interviews Karz about her experience in the New York City Ballet with type 1 diabetes. As a 21-year-old member of the New York City Ballet in 1987, Karz began to experience some common symptoms of diabetes, such as extreme thirst, constant hunger, and frequent urination. She ignored these until they began to interfere with her performances. "I went to the doctor because I was freaked out about my performance, not because I was worried about my health, " Karz says. When the diagnosis of diabetes came, it didn't exactly clear things up - at first she was told type 2 diabetes, then type 1, then type 2 again from another doctor, and finally back to type 1 diabetes.
More than half of people with diabetes who take insulin injections to control their diabetes say they have intentionally skipped an injection, with one-fifth of them reporting that they do so "sometimes" or "often, " according to a study being published this month in Diabetes Care. Using an Internet survey of more than 500 U.S. adults, the study found that 57% of survey respondents with either type 1 or type 2 diabetes purposefully failed to take their insulin shots at least occasionally. It also found that older patients, those who were disabled, those who followed a healthy diet and those with higher household incomes were more likely to take their shots at the frequency prescribed. Students, those with type 2 diabetes, and those who took more injections were more likely to skip them. Additionally, those who perceived more injection-related problems, such as interference with daily activities and injection pain and embarrassment, were more likely to skip injections. "Intentionally skipping insulin injections may be more common than clinicians think, " said lead researcher Mark Peyrot, PhD, Department of Sociology, Loyola University Maryland.
American Diabetes Association Welcomes Newest Volunteer Leader To 2010 Research Foundation Board Of Directors
The American Diabetes Association, the nation's largest and leading voluntary health organization in the fight against diabetes, is pleased to announce the newest member of its Research Foundation Board of Directors for 2010 Kenneth Moritsugu, MD, MPH of Falls Church, Virginia. Moritsugu, a native of Honolulu, Hawaii, is the current Chairman of the Johnson & Johnson Diabetes Institutes and Vice President for Global Strategic Affairs of the Johnson & Johnson Family of Diabetes Companies. Moritsugu had a 37 year career in the Commissioned Corps of the US Public Health Service. He was the Acting Surgeon General of the United States in 2002 and 2006-2007, in addition to serving as Deputy Surgeon General to Dr. David Satcher and Dr. Richard Carmona. With a diverse medical background, Moritsugu has provided consultation in health professions and systems development in Kuwait, Saudi Arabia, Nigeria, Germany, Mexico, the Trust Territory of the Pacific Islands, as well as across the United States.
Diabetes Research: New Way To Grow Embryonic Stem Cells Holds Promise Of Dramatic Reduction In Animal Use
A new method of priming early embryos to form embryonic stem (ES) cells has allowed ES cells to be derived from mice used in diabetes research for the first time. This could dramatically reduce the number of animals used to study the genetic basis of type 1 diabetes and has the potential to do the same for mouse models of other diseases too. Understanding the genetic basis of type 1 diabetes is an important area of research. Researchers often use a strain of mouse, known as the non-obese diabetic (NOD) mouse, which spontaneously develops type 1 diabetes. Previously, it was impossible to generate ES cells from NOD mice, so the only way to study a gene of interest was to breed the NOD mouse with a strain of mouse that could be genetically modified. This involved extensive breeding programmes, involving many hundreds of animals, and taking up to two years. The research has been awarded this year's annual NC3Rs 3Rs Prize. The prize, sponsored by GlaxoSmithKline, was awarded to Dr Jennifer Nichols, University of Cambridge, and her co-authors who used a precise cocktail of molecules to control the growth of the cells to generate ES cells from the NOD mouse.
Byetta LAR Will Become Decision Resources' New Clinical Gold Standard In 2013 For The Treatment Of Type 2 Diabetes
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amylin/Eli Lilly/Alkermes' Byetta LAR earns Decision Resources' proprietary clinical gold standard status in 2013 for the treatment of type 2 diabetes following its approval for the indication in 2010. Byetta LAR has competitive advantages over currently available and emerging drugs in efficacy and delivery. "Byetta LAR improves on our current gold standard, Amylin/Eli Lilly's Byetta, by offering superior glucose-lowering and weight-loss efficacy with a more convenient dosing schedule (once-weekly versus twice-daily injections), " stated Decision Resources' Analyst Christine Helliwell, Ph.D. "According to surveyed endocrinologists, Byetta LAR is expected to gain the greatest patient share among emerging type 2 diabetes therapies. Byetta LAR will primarily take patient share away from Byetta; we expect metformin to continue being the patient share leader in the future.
Clinical and basic science researchers from around the world will convene in Hong Kong from January 28 to 30 for the First International Congress on Abdominal Obesity: "Bridging the Gap between Cardiology and Diabetology." The congress, sponsored by the International Chair on Cardiometabolic Risk (ICCR), is the first-ever specialized forum for sharing new insights and evidence about abdominal obesity and its clinical and public health implications. The congress will feature panels of world-renown experts in cardiology, diabetology, lipidology, endocrinology and metabolism, obesity and nutrition, who will examine and discuss novel approaches, and share scientific and clinical data to benefit healthcare professionals, clinicians and scientists in their fight against the worldwide epidemic of abdominal obesity, diabetes, and cardiovascular disease. More than 300 presented abstracts will cover insights into the global status and significance of cardiometabolic risk, the pathophysiology of abdominal obesity and its related complications, algorithms to evaluate and measure risk, and other clinical issues that will impact the way obesity is treated.
A new evidence review suggests that using a pump to deliver insulin continuously - instead of taking three or more daily injections - might result in better control of blood sugar for people with type 1 diabetes. "The findings of this review tell us that both continuous subcutaneous insulin infusion and multiple injections correct blood glucose levels. However, [continuous infusion] may be better for reducing harmful fluctuations in blood glucose, " said lead author Marie Misso, Ph.D. Type 1 diabetes - which used to be known as juvenile diabetes - results when the pancreas is not able to secrete enough insulin, causing the levels of glucose (or sugar) in the blood to rise. Chronically high blood glucose can lead to heart attacks, circulation problems and blindness. Low levels can lead to unconsciousness and even death. Type 1 diabetes is one of the most common chronic diseases of childhood. Most people with the condition control their glucose by injecting themselves with insulin three or more times per day.
The first ever diabetes audit of 200 NHS hospitals has found that 20 per cent of patients on hospital wards have diabetes - twice the proportion previously estimated. In addition, the audit, which is due to be published later this year, will also show that people with diabetes stay in hospital longer than other patients. Access to specialist advice The Government's diabetes tsar Dr Rowan Hillson, who is leading the audit, wants to see all patients admitted to hospital with diabetes be given access to specialist advice and believes that having diabetes specialist nurses on wards can reduce readmissions of patients with diabetes, as well as drug errors, and length of stay. Ensuring the best outcomes "When they are in hospital it is crucial that people with diabetes have access to the right advice and support from healthcare professionals who have a specialist knowledge of the condition to ensure the best possible health outcomes, " said Cathy Moulton, Care Advisor at Diabetes UK.